Differentials

Systemic lupus erythematosus (SLE)

SIGNS / SYMPTOMS
INVESTIGATIONS
SIGNS / SYMPTOMS

No differentiating symptoms or signs.

INVESTIGATIONS

Negative for anti-U1 ribonucleoprotein (U1 RNP).

High antibody titers to the Smith antigen or to double-stranded DNA in the absence of anti-U1 RNP suggest SLE as the underlying diagnosis, whereas high titers to anti-U1 RNP suggest mixed connective tissue disease.

Polymyositis

SIGNS / SYMPTOMS
INVESTIGATIONS
SIGNS / SYMPTOMS

More pronounced muscle weakness than is typical of mixed connective tissue disease (MCTD); Raynaud phenomenon uncommon.

INVESTIGATIONS

Negative for anti-U1 ribonucleoproetin (U1 RNP).

High antibody titers to the Mi-2 antigen or signal recognition particle suggest dermatomyositis or polymyositis rather than overlap syndrome.

High-titer antibodies to U1 RNP suggest MCTD; antibodies to the tRNA synthetase enzymes suggest antisynthetase syndrome.

Scleroderma

SIGNS / SYMPTOMS
INVESTIGATIONS
SIGNS / SYMPTOMS

Digital ischemia and infarcts more common than in mixed connective tissue disease (MCTD); truncal sclerodermatous skin changes may also be seen, unlike in MCTD.

INVESTIGATIONS

Negative for anti-U1 ribonucleoprotein.

Antibody titers to anticentromere antibody suggest scleroderma spectrum disease rather than MCTD.

Anti-Ku and antipolymyositis/scleroderma point to a scleroderma overlap.

Idiopathic Raynaud phenomenon

SIGNS / SYMPTOMS
INVESTIGATIONS
SIGNS / SYMPTOMS

Nail fold capillaroscopy normal, digital infarcts and necrosis not seen; abnormalities suggest underlying connective tissue disease instead.

INVESTIGATIONS

Negative for anti-U1 ribonucleoprotein.

Vasculitis

SIGNS / SYMPTOMS
INVESTIGATIONS
SIGNS / SYMPTOMS

Palpable purpura or livedo reticularis suggest small and medium vessel vasculitis that are only rarely seen in mixed connective tissue disease.

INVESTIGATIONS

Negative for anti-U1 ribonucleoprotein.

Antineutrophil cytoplasmic antibodies may be seen in primary small-vessel vasculidites.

Use of this content is subject to our disclaimer